0000000000269661

AUTHOR

Sophie Paget-bailly

showing 3 related works from this author

Erratum to: Development and validation of the FRAGIRE tool for assessment an older person’s risk for frailty

2016

Background Frailty is highly prevalent in elderly people. While significant progress has been made to understand its pathogenesis process, few validated questionnaire exist to assess the multidimensional concept of frailty and to detect people frail or at risk to become frail. The objectives of this study were to construct and validate a new frailty-screening instrument named Frailty Groupe Iso-Ressource Evaluation (FRAGIRE) that accurately predicts the risk for frailty in older adults. Methods A prospective multicenter recruitment of the elderly patients was undertaken in France. The subjects were classified into financially-helped group (FH, with financial assistance) and non-financially …

Older personGerontologyRehabilitationFrailtybusiness.industryGeriatrics gerontologymedicine.medical_treatmentPublished ErratumMEDLINEEvaluation toolLoss of autonomy03 medical and health sciencesElderly0302 clinical medicinemedicine030212 general & internal medicineGeriatrics and Gerontologybusiness030217 neurology & neurosurgeryResearch ArticleBMC Geriatrics
researchProduct

Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.

2018

Abstract Background Cardiac toxicity with a decrease of the left ventricular ejection fraction (LVEF) is the main side effect induced by trastuzumab. This study reports the fluctuation of LVEF over the 12 months of adjuvant trastuzumab in PHARE trial (NCT00381901). Methods LVEF assessment was performed every 3 months while patients received trastuzumab and after completion of treatment over the first 2 years and then every 6 months afterwards. The fluctuations of LVEF over time were described and a logistic regression model was performed investigating associated factors to LVEF perfect recovery at baseline value. Results A total of 1631 patients who received 12 months of trastuzumab from PH…

Adultmedicine.medical_specialtySide effectReceptor ErbB-2medicine.medical_treatmentBreast Neoplasms030204 cardiovascular system & hematologyVentricular Function Left03 medical and health sciences0302 clinical medicineBreast cancerAntineoplastic Agents ImmunologicalTrastuzumabInternal medicinemedicineHumansIn patientcardiovascular diseasesCardiotoxicityEjection fractionbusiness.industryGeneral MedicineMiddle AgedTrastuzumabmedicine.diseaseCardiotoxicityStandard errorChemotherapy AdjuvantEchocardiography030220 oncology & carcinogenesiscardiovascular systemCardiologySurgeryFemalebusinessAdjuvantcirculatory and respiratory physiologymedicine.drugFollow-Up StudiesBreast (Edinburgh, Scotland)
researchProduct

Development and validation of the FRAGIRE tool for assessment an older person’s risk for frailty

2016

International audience; Background: Frailty is highly prevalent in elderly people. While significant progress has been made to understand its pathogenesis process, few validated questionnaire exist to assess the multidimensional concept of frailty and to detect people frail or at risk to become frail. The objectives of this study were to construct and validate a new frailty-screening instrument named Frailty Groupe Iso-Ressource Evaluation (FRAGIRE) that accurately predicts the risk for frailty in older adults.Methods: A prospective multicenter recruitment of the elderly patients was undertaken in France. The subjects were classified into financially-helped group (FH, with financial assista…

MaleGerontologyMultivariate statisticsmedicine.medical_treatmentlcsh:GeriatricsLogistic regression0302 clinical medicineElderlySurveys and QuestionnairesPrevalenceadultsProspective Studies030212 general & internal medicineelderly-peopleAged 80 and overeducation.field_of_studyRehabilitationFrailty[SDV.MHEP.GEG] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyPrognosisEvaluation tool3. Good healthLoss of autonomyFemaleFranceErratummedicine.medical_specialtyPsychometricsFrail ElderlySeparation (statistics)Population[ SDV.MHEP.GEG ] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyRisk AssessmentSensitivity and Specificity03 medical and health sciencesCronbach's alphamedicineHumanseducationGeriatric AssessmentAgedmodelbusiness.industryUnivariateReproducibility of ResultsConfidence intervallcsh:RC952-954.6Logistic ModelsPhysical therapyGeriatrics and Gerontologybusiness030217 neurology & neurosurgerydementia
researchProduct